HiFi Solves Consortium Releases Groundbreaking Study Showcasing the Clinical Research Potential of PacBio HiFi Genomes
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: Nov 05 20250mins
HiFi Sequencing Breakthrough: PacBio's HiFi sequencing, in conjunction with the Paraphase variant caller, successfully identified all 125 clinically relevant variants in a study involving 86 individuals, showcasing its potential for clinical applications in genomics.
Multi-Center Validation: The study, conducted by the HiFi Solves EMEA Consortium across five European institutions, demonstrated that HiFi sequencing can accurately phase variants and detect complex genomic events, marking a significant advancement in clinical genetics.
Cost and Efficiency Benefits: The results indicate that a single HiFi genome can replace multiple tests, streamlining the research process and reducing costs, thereby enhancing the efficiency of genetic diagnostics.
Future of Clinical Testing: The findings support the adoption of HiFi long-read sequencing in routine clinical testing and rare disease diagnostics, highlighting its robustness and reproducibility across various diagnostic laboratories.
PACB.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on PACB
Wall Street analysts forecast PACB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACB is 2.30 USD with a low forecast of 1.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.610
Low
1.50
Averages
2.30
High
3.00
Current: 1.610
Low
1.50
Averages
2.30
High
3.00
Piper Sandler
Neutral
maintain
$2
2025-11-11
Reason
Piper Sandler
Price Target
$2
2025-11-11
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on PacBio to $2 from $1.50 and keeps a Neutral rating on the shares. The firm cites the company's quarterly results for the price target change.
Stephens
Overweight
maintain
$2
2025-11-10
Reason
Stephens
Price Target
$2
2025-11-10
maintain
Overweight
Reason
Stephens raised the firm's price target on PacBio to $2 from $1.80 and keeps an Overweight rating on the shares. While noting that the company reported Q3 results that missed expectations, the firm thinks expanding Revio utilization has potential to support upside to its consumable estimates and contends that NIH clarity could drive stronger instruments than it models.
Piper Sandler
Neutral
maintain
2025-08-11
Reason
Piper Sandler
Price Target
2025-08-11
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on PacBio to $1.50 from $1.25 following quarterly results. The firm keeps a Neutral rating on the shares.
Bernstein
Eve Burstein
Outperform
maintain
2025-08-08
Reason
Bernstein
Eve Burstein
Price Target
2025-08-08
maintain
Outperform
Reason
Bernstein analyst Eve Burstein raised the firm's price target on PacBio to $1.70 from $1.50 and keeps an Outperform rating on the shares. The firm notes PacBio reported 2Q25 results Thursday, with revenue of $39.8M 9% above consensus estimates of $36.6M. The company narrowed FY25 revenue guidance, but raised the gross margin guide and lowered the OpEx guide, Bernstein adds.
See All Ratings
About PACB
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?